Reading an article about Cancer Research at Memorial Sloan Kettering (NYC) lead me here:
(Clinical Studies using PEMF therapy in Oncology.
Whoever is interested in the subject can read the entire article at the link below) It's fascinating.
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
Maria Vadalà, Julio Cesar Morales‐Medina, [...], and Tommaso Iannitti
"The use of PEMF therapy in oncology is still limited (Table 3) 4. The first study utilizing PEMF therapy was conducted by Barbault and coworkers who hypothesized that a combination of specific frequencies, defined tumor‐specific frequencies, may display therapeutic effectiveness for localized treatment of tumors 15. They identified a total of 1524 tumor‐specific frequencies, ranging from 0.1 to 114 kHz, consisting in the measurement of variations in skin electrical resistance, pulse amplitude, and blood pressure in 163 patients affected by different types of cancer including brain tumors, colorectal cancer, HCC carcinoma, pancreatic, colorectal, ovarian, breast, prostate, lung, thyroid, and bladder cancer and exposed to the radiofrequency system. Self‐administered PEMF therapy for 60 min, three times a day, for an average of 278.4 months was offered to only 28 patients with advanced cancer (breast cancer [n = 7], ovarian cancer.....
None of the patients who received PEMF therapy reported any side effects; four patients presented stable disease for 3 years (thyroid cancer with biopsy‐proven lung metastases), 6 months (mesothelioma metastatic to the abdomen), 5 months (non‐small‐cell lung cancer), and 4 months (pancreatic cancer with biopsy‐proven liver metastases), respectively.
PEMF therapy has also been employed for the treatment of HCC. Therapies for this disease are needed, especially for patients at an advanced disease stage who cannot tolerate chemotherapy or intrahepatic interventions because of impaired liver function 101. The feasibility of PEMF therapy for treatment of HCC has also been investigated in a single‐group, open‐label, phase I/II clinical study 102. Forty‐one patients with advanced HCC received very low levels of PEMFs modulated at HCC‐specific frequencies (100 Hz–21 kHz) and received three‐daily 60 min outpatient treatments. No adverse reactions were observed during PEMF treatment. Five patients reported complete disappearance and two patients reported decrease in pain shortly after beginning of treatment.
Four patients showed a partial response to treatment, while 16 patients (39%) had stable disease for more than 12 weeks. This study shows that PEMF therapy provides a safe and well‐tolerated treatment, as well as evidence of antineoplastic effects in patients with HCC.
In summary, encouraging findings warrant randomized clinical studies to determine the effectiveness of amplitude‐modulated PEMF therapy that can delay cancer progression and increase overall survival in patients. The increased knowledge of tumor‐specific frequencies and the preliminary evidence that additional tumor‐specific frequencies may yield a therapeutic benefit provide a strong rationale for the novel concept that administration of a large number of these frequencies may result in successful long‐term disease management."
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119968/
(Clinical Studies using PEMF therapy in Oncology.
Whoever is interested in the subject can read the entire article at the link below) It's fascinating.
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
Maria Vadalà, Julio Cesar Morales‐Medina, [...], and Tommaso Iannitti
"The use of PEMF therapy in oncology is still limited (Table 3) 4. The first study utilizing PEMF therapy was conducted by Barbault and coworkers who hypothesized that a combination of specific frequencies, defined tumor‐specific frequencies, may display therapeutic effectiveness for localized treatment of tumors 15. They identified a total of 1524 tumor‐specific frequencies, ranging from 0.1 to 114 kHz, consisting in the measurement of variations in skin electrical resistance, pulse amplitude, and blood pressure in 163 patients affected by different types of cancer including brain tumors, colorectal cancer, HCC carcinoma, pancreatic, colorectal, ovarian, breast, prostate, lung, thyroid, and bladder cancer and exposed to the radiofrequency system. Self‐administered PEMF therapy for 60 min, three times a day, for an average of 278.4 months was offered to only 28 patients with advanced cancer (breast cancer [n = 7], ovarian cancer.....
None of the patients who received PEMF therapy reported any side effects; four patients presented stable disease for 3 years (thyroid cancer with biopsy‐proven lung metastases), 6 months (mesothelioma metastatic to the abdomen), 5 months (non‐small‐cell lung cancer), and 4 months (pancreatic cancer with biopsy‐proven liver metastases), respectively.
PEMF therapy has also been employed for the treatment of HCC. Therapies for this disease are needed, especially for patients at an advanced disease stage who cannot tolerate chemotherapy or intrahepatic interventions because of impaired liver function 101. The feasibility of PEMF therapy for treatment of HCC has also been investigated in a single‐group, open‐label, phase I/II clinical study 102. Forty‐one patients with advanced HCC received very low levels of PEMFs modulated at HCC‐specific frequencies (100 Hz–21 kHz) and received three‐daily 60 min outpatient treatments. No adverse reactions were observed during PEMF treatment. Five patients reported complete disappearance and two patients reported decrease in pain shortly after beginning of treatment.
Four patients showed a partial response to treatment, while 16 patients (39%) had stable disease for more than 12 weeks. This study shows that PEMF therapy provides a safe and well‐tolerated treatment, as well as evidence of antineoplastic effects in patients with HCC.
In summary, encouraging findings warrant randomized clinical studies to determine the effectiveness of amplitude‐modulated PEMF therapy that can delay cancer progression and increase overall survival in patients. The increased knowledge of tumor‐specific frequencies and the preliminary evidence that additional tumor‐specific frequencies may yield a therapeutic benefit provide a strong rationale for the novel concept that administration of a large number of these frequencies may result in successful long‐term disease management."
Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119968/
2
